MDGL
Price
$337.54
Change
+$6.22 (+1.88%)
Updated
Nov 5, 04:00 PM (EDT)
113 days until earnings call
NKTR
Price
$1.39
Change
+$0.06 (+4.51%)
Updated
Nov 5, 04:00 PM (EDT)
2 days until earnings call
Ad is loading...

MDGL vs NKTR

Header iconMDGL vs NKTR Comparison
Open Charts MDGL vs NKTRBanner chart's image
Madrigal Pharmaceuticals
Price$337.54
Change+$6.22 (+1.88%)
Volume$59.28K
CapitalizationN/A
Nektar Therapeutics
Price$1.39
Change+$0.06 (+4.51%)
Volume$300.64K
CapitalizationN/A
View a ticker or compare two or three
MDGL vs NKTR Comparison Chart
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NKTR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
MDGL vs. NKTR commentary
Nov 06, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Buy and NKTR is a StrongBuy.

COMPARISON
Comparison
Nov 06, 2024
Stock price -- (MDGL: $331.32 vs. NKTR: $1.34)
Brand notoriety: MDGL: Not notable vs. NKTR: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 280% vs. NKTR: 479%
Market capitalization -- MDGL: $7.36B vs. NKTR: $257.71M
MDGL [@Biotechnology] is valued at $7.36B. NKTR’s [@Biotechnology] market capitalization is $257.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $488.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 1 FA rating(s) are green whileNKTR’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 1 green, 4 red.
  • NKTR’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than NKTR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 5 TA indicator(s) are bullish while NKTR’s TA Score has 6 bullish TA indicator(s).

  • MDGL’s TA Score: 5 bullish, 6 bearish.
  • NKTR’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, NKTR is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а +52.68% price change this week, while NKTR (@Biotechnology) price change was -1.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.79%. For the same industry, the average monthly price growth was +15.00%, and the average quarterly price growth was +10.61%.

Reported Earning Dates

MDGL is expected to report earnings on Feb 26, 2025.

NKTR is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (+4.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($7.23B) has a higher market cap than NKTR($247M). NKTR YTD gains are higher at: 137.168 vs. MDGL (43.193). NKTR has higher annual earnings (EBITDA): -146.03M vs. MDGL (-502.65M). MDGL has more cash in the bank: 999M vs. NKTR (271M). NKTR has less debt than MDGL: NKTR (112M) vs MDGL (119M). NKTR has higher revenues than MDGL: NKTR (93.2M) vs MDGL (76.8M).
MDGLNKTRMDGL / NKTR
Capitalization7.23B247M2,926%
EBITDA-502.65M-146.03M344%
Gain YTD43.193137.16831%
P/E RatioN/AN/A-
Revenue76.8M93.2M82%
Total Cash999M271M369%
Total Debt119M112M106%
FUNDAMENTALS RATINGS
MDGL vs NKTR: Fundamental Ratings
MDGL
NKTR
OUTLOOK RATING
1..100
2672
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
25100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3944
P/E GROWTH RATING
1..100
10087
SEASONALITY SCORE
1..100
n/a31

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NKTR's Valuation (58) in the Biotechnology industry is in the same range as MDGL (70) in the Pharmaceuticals Other industry. This means that NKTR’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (25) in the Pharmaceuticals Other industry is significantly better than the same rating for NKTR (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than NKTR’s over the last 12 months.

MDGL's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as NKTR (98) in the Biotechnology industry. This means that MDGL’s stock grew similarly to NKTR’s over the last 12 months.

MDGL's Price Growth Rating (39) in the Pharmaceuticals Other industry is in the same range as NKTR (44) in the Biotechnology industry. This means that MDGL’s stock grew similarly to NKTR’s over the last 12 months.

NKTR's P/E Growth Rating (87) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that NKTR’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLNKTR
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 14 days ago
81%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Ad is loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NKTR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IMCGX9.930.02
+0.20%
Transamerica Mid Cap Growth I
ASVHX11.100.02
+0.18%
American Century Small Cap Value G
FMUIX14.710.01
+0.07%
Federated Hermes Muni and Stock Adv IS
DTCCX15.32-0.09
-0.58%
BNY Mellon Sust US Equity C
RYTSX50.82-0.38
-0.74%
Rydex Transportation A

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with VXRT. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then VXRT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+3.67%
VXRT - MDGL
61%
Loosely correlated
-5.83%
ALXO - MDGL
56%
Loosely correlated
+2.76%
REPL - MDGL
55%
Loosely correlated
+0.92%
ZNTL - MDGL
51%
Loosely correlated
+12.20%
CGEM - MDGL
50%
Loosely correlated
+0.76%
More

NKTR and

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTR has been loosely correlated with DNLI. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTR
1D Price
Change %
NKTR100%
+8.94%
DNLI - NKTR
43%
Loosely correlated
+0.59%
NTLA - NKTR
43%
Loosely correlated
+2.30%
SLS - NKTR
42%
Loosely correlated
-2.10%
MDGL - NKTR
38%
Loosely correlated
+3.67%
ATAI - NKTR
37%
Loosely correlated
+0.46%
More